Mersana Competitors
| MRSN Stock | USD 29.08 0.18 0.62% |
Mersana Therapeutics vs Xilio Development Correlation
Pay attention - limited upside
The correlation between Mersana Therapeutics and XLO is -0.81 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Mersana Therapeutics and XLO in the same portfolio, assuming nothing else is changed.
Moving together with Mersana Stock
Moving against Mersana Stock
| 0.87 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.81 | ABP | Abpro Holdings | PairCorr |
| 0.79 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.77 | EDIT | Editas Medicine | PairCorr |
| 0.77 | GNLX | Genelux Common | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mersana Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mersana Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mersana Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Mersana and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mersana Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Mersana Stock performing well and Mersana Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mersana Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KZR | 0.71 | (0.06) | 0.00 | (0.22) | 0.00 | 1.46 | 7.79 | |||
| ALGS | 4.58 | (0.21) | 0.00 | 4.49 | 0.00 | 10.16 | 28.43 | |||
| FGEN | 2.66 | (0.19) | 0.00 | 0.60 | 0.00 | 4.33 | 28.75 | |||
| OKUR | 3.80 | (0.49) | 0.00 | (0.72) | 0.00 | 6.64 | 25.44 | |||
| TPST | 4.81 | (1.85) | 0.00 | (2.74) | 0.00 | 7.92 | 57.69 | |||
| XFOR | 3.20 | (0.11) | 0.00 | (0.03) | 0.00 | 7.57 | 23.09 | |||
| BRNS | 3.18 | (0.79) | 0.00 | (6.39) | 0.00 | 5.71 | 24.01 | |||
| INMB | 3.61 | (0.35) | 0.00 | (0.18) | 0.00 | 6.82 | 22.66 | |||
| BCAB | 7.12 | (1.31) | 0.00 | 0.44 | 0.00 | 15.28 | 66.15 | |||
| XLO | 2.26 | (0.64) | 0.00 | (0.80) | 0.00 | 4.23 | 15.41 |
Cross Equities Net Income Analysis
Compare Mersana Therapeutics and related stocks such as Kezar Life Sciences, Aligos Therapeutics, and FibroGen Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.5 M) | (23.2 M) | (31.5 M) | (39 M) | (54.6 M) | (65.3 M) | (101.9 M) | (83.7 M) | (75.4 M) | (71.6 M) |
| ALGS | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (52.3 M) | (108.5 M) | (128.3 M) | (96 M) | (87.7 M) | (131.2 M) | (118.1 M) | (124 M) |
| OKUR | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (39.8 M) | (29.5 M) | (35.3 M) | (52.7 M) | (47.4 M) | (49.8 M) |
| TPST | (2.7 M) | (2.7 M) | (13.5 M) | (29 M) | (49.5 M) | (73.2 M) | (82.3 M) | (84.6 M) | (27.2 M) | (44.6 M) | (19.1 M) | (28.3 M) | (35.7 M) | (29.5 M) | (41.8 M) | (37.7 M) | (39.5 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (56.6 M) | (62.1 M) | (88.7 M) | (93.9 M) | (101.2 M) | (37.5 M) | (33.7 M) | (35.4 M) |
| BRNS | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (17.7 M) | (50.9 M) | 5.3 M | (73.3 M) | (61.1 M) | (55 M) | (57.7 M) |
| INMB | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (277 K) | (831 K) | (12.4 M) | (7.7 M) | (12.1 M) | (30.3 M) | (28.6 M) | (30 M) | (42.1 M) | (37.9 M) | (36 M) |
| BCAB | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29.8 M) | (35.9 M) | (95.4 M) | (105.3 M) | (123.5 M) | (69.8 M) | (62.8 M) | (65.9 M) |
| XLO | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (55.2 M) | (74.3 M) | (87.3 M) | (76.4 M) | (58.2 M) | (52.4 M) | (55 M) |
Mersana Therapeutics and related stocks such as Kezar Life Sciences, Aligos Therapeutics, and FibroGen Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Mersana Therapeutics financial statement analysis. It represents the amount of money remaining after all of Mersana Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Mersana Therapeutics Competitive Analysis
The better you understand Mersana Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mersana Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mersana Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Mersana Therapeutics Competition Performance Charts
Five steps to successful analysis of Mersana Therapeutics Competition
Mersana Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mersana Therapeutics in relation to its competition. Mersana Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Mersana Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mersana Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mersana Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Mersana Therapeutics position
In addition to having Mersana Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Artificial Intelligence Thematic Idea Now
Artificial Intelligence
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Will Biotechnology sector continue expanding? Could Mersana diversify its offerings? Factors like these will boost the valuation of Mersana Therapeutics. Expected growth trajectory for Mersana significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mersana Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (13.95) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Investors evaluate Mersana Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mersana Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mersana Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Mersana Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mersana Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mersana Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.